.START 

Bio-Technology General Corp., a health-care products concern, named Christopher Illick to its five-member board. 

Mr. Illick, general counsel and corporate secretary of Clarendon America Insurance Co., fills the seat vacated by Frederick R. Adler.
Mr. Adler, who resigned, is a venture capitalist who controls 13.4% of Bio-Technology common. 

The company said it is waiting to hear from the Securities and Exchange Commission about Bio-Technology's plan for debt restructuring.
Major holders have approved the plan.
Without such a restructuring or additional financing, the company faced the prospect of a bankruptcy-law filing. 

